The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is the first clinical trial conducted by the American Society of Clinical Oncology (ASCO), the world’s leading professional organization representing physicians who care for people with cancer. Clinical trials are research studies that involve patients. The TAPUR Study is a clinical trial for people with later-stage cancer, focused on whether specific targeted therapies can benefit more patients and lead to more personalized therapies.
Who can join the TAPUR Study?
Specifically, the TAPUR Study is a clinical trial for adults diagnosed with advanced cancer for whom:
standard treatment hasn’t worked,
standard treatment has stopped working, or
there is no standard treatment for that type and stage of cancer.
In addition, the person’s cancer must also have at least one genomic variation that can be targeted with specific drugs. This means that a special laboratory test -- called a genomic or molecular profiling test -- has been performed on a sample of your tumor.
All drugs used in the TAPUR Study are approved by the U.S. Food and Drug Administration (FDA) for the treatment of specific types of cancer. However, the TAPUR Study is researching whether those drugs might work in treating other types of cancer too, so the drug you receive will not be FDA-approved specifically for your type of cancer. Each patient who enrolls in the TAPUR Study will be matched up with a targeted therapy based on his or her tumor’s specific genomic variation. There are additional criteria for patients interested in joining this clinical trial.
How can I learn more?
Listen to a brief podcast, or watch this video to learn more about the TAPUR Study:
Read a full-text transcript (txt).
Learn more about the enrollment requirements, study locations, and specific drugs available in the study, at www.TAPUR.org/patients. Please note that this link takes you to a separate ASCO website. You can also contact the study team via email at TAPUR@asco.org.
Last reviewed: March 26, 2018